| 초록 |
Objectives: Introduction: The high flux dialyzers in standard hemodialysis offer numerous benefits for ESRD patient. New dialyzer with a medium cut-off membrane(Theranova®, Baxter Healthcare), featuring an innovative membrane, effectively targets large middle molecules not efficiently removed by currently available dialysis treatment. We evaluated the efficacy of Theranova® dialyzer on the uremic pruritus in patients on maintenance hemodialysis..
Methods: Method: Seventeen end-stage renal failure patients complaining of uremic pruritus on maintenance hemodialysis for more than 3 months were included in this study. All patient underwent three sessions of regular maintenance hemodialysis per week with Theranova® dialyzer instead of previous conventional Revaclear® dialyzer(Baxter). The magnitude of itching was assessed with 5-D itch scale and visual analogue scale (VAS). And we compared the data of blood chemistry, hematocrit, Kt/V and itching with baseline values, 3 months after switching to Theranova® dialyzer(Baxter).
Results: Results: Theranova® dialyzer was well accepted by all the patients and no serious adverse event was observed. The main results are showen in Table 1. Data are reported as mean ± standard deviation(SD). 5-D itching scale showed a tendency of improvement of uremic pruritus, 3 months after switching to new dialyzer but there was no statically significant difference. Other data did not show significant difference.
Conclusions: Conclusion: In a short-term, hemodialysis with Theranova® dialyzer showed a tendency of improvement of uremic pruritus but statically not significant.
Table1. Comparison baseline and after 3-months data
|